Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria

Brodsky, RA, Peffault de Latour, R, Rottinghaus, ST et al. (15 more authors) (2020) Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria. Haematologica. ISSN 0390-6078

Abstract

Metadata

Authors/Creators:
  • Brodsky, RA
  • Peffault de Latour, R
  • Rottinghaus, ST
  • Röth, A
  • Risitano, AM
  • Weitz, IC
  • Hillmen, P ORCID logo https://orcid.org/0000-0001-5617-4403
  • Maciejewski, JP
  • Szer, J
  • Lee, JW
  • Kulasekararaj, AG
  • Volles, L
  • Damokosh, AI
  • Ortiz, S
  • Shafner, L
  • Liu, P
  • Hill, A
  • Schrezenmeier, H
Keywords: paroxysmal nocturnal hemoglobinuria; complement inactivating agents; hemolysis; thrombosis
Dates:
  • Accepted: 9 January 2020
  • Published (online): 16 January 2020
Institution: The University of Leeds
Depositing User: Symplectic Publications
Date Deposited: 15 Jan 2020 15:20
Last Modified: 19 Feb 2020 16:30
Status: Published online
Publisher: Ferrata Storti Foundation
Identification Number: https://doi.org/10.3324/haematol.2019.236877

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Export

Statistics